<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295997</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000463522</org_study_id>
    <secondary_id>UCSF-01251</secondary_id>
    <secondary_id>UCSF-H5010-19585-05</secondary_id>
    <secondary_id>UCSF-2101</secondary_id>
    <nct_id>NCT00295997</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia</brief_title>
  <official_title>Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem&#xD;
      cells that closely match the patient's stem cells, helps stop the growth of cancer cells. It&#xD;
      also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune system and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor&#xD;
      lymphocyte infusion) after the transplant may help increase this effect. Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate&#xD;
      mofetil after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well a donor stem cell transplant works in&#xD;
      treating patients with hematologic cancer, metastatic kidney cancer, or aplastic anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the treatment-related mortality (TRM) rate at 100 days in patients with&#xD;
           hematologic malignancy, metastatic renal cell carcinoma, or aplastic anemia undergoing&#xD;
           nonmyeloablative allogeneic stem cell transplantation using matched unrelated donors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the TRM at 12 months in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 6-month engraftment rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine 1-year overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Nonmyeloablative preparative regimen: Patients receive fludarabine IV over 30 minutes on&#xD;
           days -7 to -3, busulfan* IV over 6 hours on days -4 and -3, and anti-thymocyte globulin&#xD;
           IV over 6-10 hours on days -4 to -1.&#xD;
&#xD;
      NOTE: *Patients with aplastic anemia receive cyclophosphamide IV over 2 hours on days -6 to&#xD;
      -3 instead of busulfan.&#xD;
&#xD;
        -  Allogeneic stem cell reinfusion: Patients undergo allogeneic bone marrow or peripheral&#xD;
           blood stem cell transplantation on day 0. Patients then receive filgrastim (G-CSF)&#xD;
           subcutaneously daily beginning on day 7 and continuing until blood counts recover.&#xD;
&#xD;
        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus orally twice daily&#xD;
           or IV continuously beginning on day -2 and continuing for approximately for 6-12 months&#xD;
           after transplantation. Patients also receive mycophenolate mofetil orally or IV twice&#xD;
           daily on days 0 to 60 and methotrexate IV on days 1, 3, 6, and 11**.&#xD;
&#xD;
      NOTE: **Patients with aplastic anemia receive methotrexate IV on days 1, 3, and 6 (not day&#xD;
      11).&#xD;
&#xD;
        -  Donor lymphocyte infusion (DLI): After day 180, patients with no evidence of active GVHD&#xD;
           may receive DLI. A second DLI may be infused &gt; 8 weeks after the first in the absence of&#xD;
           disease response or GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Aplastic anemia not responsive to immunosuppressive therapy&#xD;
&#xD;
               -  Metastatic renal cell carcinoma&#xD;
&#xD;
               -  Hematologic malignancy, including any of the following:&#xD;
&#xD;
                    -  Acute myeloid leukemia (AML)* not curable with chemotherapy and meeting any&#xD;
                       of the following criteria:&#xD;
&#xD;
                         -  AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q,&#xD;
                            complex, Philadelphia chromosome-positive [Ph+])&#xD;
&#xD;
                         -  AML evolved from prior myelodysplasia&#xD;
&#xD;
                         -  AML secondary to prior chemotherapy&#xD;
&#xD;
                         -  Failed to achieve remission&#xD;
&#xD;
                         -  In second or subsequent remission NOTE: *Marrow blasts &lt; 10%- can be&#xD;
                            achieved by chemotherapy&#xD;
&#xD;
                    -  Myelodysplasia* with any of the following high-risk features:&#xD;
&#xD;
                         -  Adverse cytogenetics (-7, 7q, -5, -5q, complex)&#xD;
&#xD;
                         -  Excess blasts&#xD;
&#xD;
                         -  Prior conversion to AML&#xD;
&#xD;
                         -  Severe cytopenias with absolute neutrophil count &lt; 500/mm^3 or platelet&#xD;
                            count &lt; 20,000/mm^3 NOTE: *Marrow blasts &lt; 10%- can be achieved by&#xD;
                            chemotherapy&#xD;
&#xD;
                    -  Acute lymphoblastic leukemia (ALL)* not curable with chemotherapy and&#xD;
                       meeting any of the following criteria:&#xD;
&#xD;
                         -  High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)&#xD;
&#xD;
                         -  More than 1 induction course required to achieve remission&#xD;
&#xD;
                         -  Failed to enter remission&#xD;
&#xD;
                         -  In second or subsequent remission NOTE: *Marrow blasts &lt; 10 %&#xD;
&#xD;
                    -  Chronic lymphocytic leukemia (CLL) with high-risk features, including any of&#xD;
                       the following:&#xD;
&#xD;
                         -  Refractory to initial or subsequent therapy&#xD;
&#xD;
                         -  Progression after initial response to therapy&#xD;
&#xD;
                         -  Prolymphocytic morphology&#xD;
&#xD;
                    -  Follicular lymphoma with any of the following high-risk features:&#xD;
&#xD;
                         -  Refractory to initial or subsequent therapy&#xD;
&#xD;
                         -  Progression after response to initial therapy&#xD;
&#xD;
                         -  Has â‰¥ 3 International Prognostic Index (IPI) risk factors&#xD;
&#xD;
                    -  Multiple myeloma&#xD;
&#xD;
                         -  Stage II-III disease confirmed at diagnosis or after initial&#xD;
                            progression&#xD;
&#xD;
                    -  Other lymphoma that has failed to respond to primary therapy, progressed, or&#xD;
                       recurred after prior therapy, including any of the following:&#xD;
&#xD;
                         -  Diffuse large cell lymphoma&#xD;
&#xD;
                         -  Mantle cell lymphoma&#xD;
&#xD;
                         -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Myeloproliferative disease with evidence of disease acceleration, including&#xD;
                       any of the following:&#xD;
&#xD;
                         -  Myelofibrosis&#xD;
&#xD;
                         -  Polycythemia vera&#xD;
&#xD;
                         -  Essential thrombocythemia&#xD;
&#xD;
                    -  Chronic myeloid leukemia (CML) that failed to be controlled by imatinib&#xD;
                       mesylate&#xD;
&#xD;
          -  Disease must be stable or responding to therapy&#xD;
&#xD;
          -  No rapid progression of malignant disease&#xD;
&#xD;
               -  Expected time to disease progression &gt; 12 weeks&#xD;
&#xD;
          -  Not eligible for autologous stem cell transplantation&#xD;
&#xD;
          -  Matched unrelated donor available&#xD;
&#xD;
               -  9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Bilirubin &lt; 3 mg/dL&#xD;
&#xD;
               -  Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is&#xD;
                  normal&#xD;
&#xD;
          -  AST &lt; 4 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis C or B allowed provided bilirubin and AST are normal&#xD;
&#xD;
          -  Cardiac ejection fraction &gt; 30%&#xD;
&#xD;
          -  DLCO &gt; 40% of predicted&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled active infection requiring ongoing antibiotic treatment&#xD;
&#xD;
          -  No poor performance status&#xD;
&#xD;
          -  No poor organ function&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior stem cell or bone marrow transplantation allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles A. Linker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

